Back to results

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Primary Purpose

Active Psoriatic Arthritis

Status

Recruiting

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

TILD

matching placebo injections

About this trial

This is an interventional treatment trial for Active Psoriatic Arthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subject has provided written informed consent.
Subject is ≥ 18 years of age at time of Screening.
RF and anti-CCP Ab negative.
Subjects must have prior exposure to anti-TNF agent(s) use for the treatment of PsO or PsA.

Exclusion Criteria:

Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition.
Subject has an active infection or history of infections as follows:
- any active infection for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening,
- a serious infection, defined as requiring hospitalization or IV anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening,
- recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
Subject had myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose.
Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
Subject has a history of malignancy within 5 years from the time of Screening EXCEPT treated and considered cured cutaneous basal or squamous cell carcinoma, in situ cervical carcinoma, OR in situ breast ductal carcinoma.
Subjects with a history of alcohol or drug abuse in the previous 2 years.
Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 17 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A FSH test should be performed to confirm menopause for those women with no menses for less than 1 year.
Subject currently enrolled in another investigational device/procedure or drug study, or Baseline of this study is less than 30 days or 5 half-lives (whichever is longer) since ending another investigational device/procedure or drug study(s), or receiving other investigational agent(s).
Subject previously has been enrolled (randomized) in this study.
Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
Donation or loss of 400 mL or more of blood within 8 weeks before dosing.
Subjects who have been placed in an institution on official or judicial orders.
Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arm A

Arm B

Arm Description

Outcomes

Primary Outcome Measures

The proportion of subjects who achieve American College of Rheumatology [ACR20]

the proportion of subjects achieving a 20% reduction from Baseline in response criteria

Secondary Outcome Measures

The proportion of subjects achieving American College of Rheumatology [ACR50]

the proportion of subjects achieving a 50% reduction from Baseline in response criteria

The proportion of subjects achieving American College of Rheumatology [ACR70]

the proportion of subjects achieving a 70% reduction from Baseline in response criteria

The proportion of subjects achieving Psoriasis Area and Severity Index 75 response among subjects with Body surface area ≥3% at baseline

The change from Baseline in the van der Heijde modified total Sharp score

Change from Baseline in American College of Rheumatology Response Criteria Components Score

Tender Joint Count (68), Swollen Joint Count (66), Physician's Global Assessment of Arthritis (Visual Analog Scale, 0-100), Patient's Global Assessment of Arthritis (Visual Analog Scale, 0-100), Patient's Assessment of Arthritis Pain (Visual Analog Scale, 0-100), C-reactive protein levels, Erythrocyte sedimentation rate levels

change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index

change from Baseline in Leeds Enthesitis Index

The change from Baseline in Leeds Dactylitis Index

The proportion of subjects who achieve a disease activity score-C-reactive protein < 3.2

The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)

The proportion of subjects with the Change in van der Heijde modified total Sharp score <0 and < 0.5

The proportion of subjects with active Psoriasis and Body surface area ≥3%

with: Psoriasis Area and Severity Index 90 and Psoriasis Area and Severity Index 100

The change from Baseline in subjects with active Psoriasis and Body surface area ≥ 3% ("those with involvement of nails" )

Physician Global Assessment-Psoriasis and nail psoriasis severity index

The proportion of subjects achieving American College of Rheumatology [ACR20, ACR50 and ACR70]

the proportion of subjects achieving a 20/50/70% reduction from Baseline in response criteria

The change from Baseline in American College of Rheumatology Response Criteria Components Score

The change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index

The change from Baseline

Leeds Enthesitis Index, Leeds Dactylitis Index, Health Assessment Questionnaire Disability Index Score

The proportion of subjects who achieve a Disease Activity Score(28 [joints]-C-reactive protein) < 3.2

The change from Baseline in van der Heijde modified total Sharp score

The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)

The proportion of subjects with the change in van der Heijde modified total Sharp score <0 and < 0.5

In subjects with active Psoriasis and Body surface area ≥3%, the proportion of subjects

Psoriasis Area and Severity Index 75, Psoriasis Area and Severity Index 90 and Psoriasis Area and Severity Index 100

In subjects with active Psoriasis and Body surface area ≥3% those with involvement of nails , the change from Baseline in nail psoriasis severity index

In subjects with active Psoriasis and Body surface area ≥3%, the change from Baseline in Physician Global Assessment-Psoriasis

Change from baseline in health assessment questionnaire - disability index (HAQ-DI) score

The change from Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components

Physical Functioning Domain, Role-Physical Domain, Role-Emotional Domain, Bodily Pain Domain, Mental Health Domain, General Health Domain, Vitality Domain, Social Functioning Domain, Physical Component Summary Score, Mental Component Summary Score

The change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scores

Full Information

NCT ID

NCT04314544

First Posted

March 13, 2020

Last Updated

September 5, 2023

Sponsor

Sun Pharmaceutical Industries Limited

1. Study Identification

Unique Protocol Identification Number

NCT04314544

Brief Title

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Official Title

A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Recruiting

Study Start Date

July 1, 2020 (Actual)

Primary Completion Date

June 2024 (Anticipated)

Study Completion Date

March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sun Pharmaceutical Industries Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Active Psoriatic Arthritis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

Outcomes Assessor

Allocation

Randomized

Enrollment

472 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Arm A

Arm Type

Experimental

Arm Title

Arm B

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

TILD

Intervention Description

one 1 mL injection of study medication

Intervention Type

Drug

Intervention Name(s)

matching placebo injections

Intervention Description

one 1 mL injection of placebo

Primary Outcome Measure Information:

Title

The proportion of subjects who achieve American College of Rheumatology [ACR20]

Description

the proportion of subjects achieving a 20% reduction from Baseline in response criteria

Time Frame

at week 24

Secondary Outcome Measure Information:

Title

The proportion of subjects achieving American College of Rheumatology [ACR50]

Description

the proportion of subjects achieving a 50% reduction from Baseline in response criteria

Time Frame

at Week 24

Title

The proportion of subjects achieving American College of Rheumatology [ACR70]

Description

the proportion of subjects achieving a 70% reduction from Baseline in response criteria

Time Frame

at Week 24

Title

The proportion of subjects achieving Psoriasis Area and Severity Index 75 response among subjects with Body surface area ≥3% at baseline

Time Frame

at Weeks 24

Title

The change from Baseline in the van der Heijde modified total Sharp score

Time Frame

at Week 24

Title

The change from Baseline in the van der Heijde modified total Sharp score

Time Frame

at Week 16

Title

Change from Baseline in American College of Rheumatology Response Criteria Components Score

Description

Time Frame

at Week 24

Title

change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index

Time Frame

at Week 24

Title

change from Baseline in Leeds Enthesitis Index

Time Frame

at Week 24

Title

The change from Baseline in Leeds Dactylitis Index

Time Frame

at Week 24

Title

The proportion of subjects who achieve a disease activity score-C-reactive protein < 3.2

Time Frame

at Week 24

Title

The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)

Time Frame

at Week 24

Title

The proportion of subjects with the Change in van der Heijde modified total Sharp score <0 and < 0.5

Time Frame

at Week 24.

Title

The proportion of subjects with active Psoriasis and Body surface area ≥3%

Description

with: Psoriasis Area and Severity Index 90 and Psoriasis Area and Severity Index 100

Time Frame

at Week 24

Title

The change from Baseline in subjects with active Psoriasis and Body surface area ≥ 3% ("those with involvement of nails" )

Description

Physician Global Assessment-Psoriasis and nail psoriasis severity index

Time Frame

at Week 24

Title

The proportion of subjects achieving American College of Rheumatology [ACR20, ACR50 and ACR70]

Description

the proportion of subjects achieving a 20/50/70% reduction from Baseline in response criteria

Time Frame

at week 52

Title

The change from Baseline in American College of Rheumatology Response Criteria Components Score

Description

Time Frame

at Week 52

Title

The change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index

Time Frame

at Week 52

Title

The change from Baseline

Description

Leeds Enthesitis Index, Leeds Dactylitis Index, Health Assessment Questionnaire Disability Index Score

Time Frame

at Week 52

Title

The proportion of subjects who achieve a Disease Activity Score(28 [joints]-C-reactive protein) < 3.2

Time Frame

at Week 52

Title

The change from Baseline in van der Heijde modified total Sharp score

Time Frame

at Week 52

Title

The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)

Time Frame

at Week 52

Title

The proportion of subjects with the change in van der Heijde modified total Sharp score <0 and < 0.5

Time Frame

at Week 52

Title

In subjects with active Psoriasis and Body surface area ≥3%, the proportion of subjects

Description

Psoriasis Area and Severity Index 75, Psoriasis Area and Severity Index 90 and Psoriasis Area and Severity Index 100

Time Frame

at Week 52

Title

In subjects with active Psoriasis and Body surface area ≥3% those with involvement of nails , the change from Baseline in nail psoriasis severity index

Time Frame

at Week 52

Title

In subjects with active Psoriasis and Body surface area ≥3%, the change from Baseline in Physician Global Assessment-Psoriasis

Time Frame

at Week 52

Title

Change from baseline in health assessment questionnaire - disability index (HAQ-DI) score

Time Frame

at Week 24

Title

The change from Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components

Description

Time Frame

Weeks 24 and 52

Title

The change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scores

Time Frame

at Week 24

Other Pre-specified Outcome Measures:

Title

The proportion of subjects achieving American College of Rheumatology [ACR20]

Description

the proportion of subjects achieving a 20% reduction from Baseline in response criteria

Time Frame

Weeks 24 and 52

Title

The proportion of subjects achieving American College of Rheumatology [ACR50]

Description

the proportion of subjects achieving a 50% reduction from Baseline in response criteria

Time Frame

Weeks 24 and 52

Title

The proportion of subjects achieving American College of Rheumatology [ACR70]

Description

the proportion of subjects achieving a 70% reduction from Baseline in response criteria

Time Frame

Weeks 24 and 52

Title

The change from Baseline in American College of Rheumatology Response Criteria Components Score

Description

Time Frame

Weeks 24 and 52

Title

The change from Baseline

Description

Leeds Enthesitis Index, Leeds Dactylitis Index, Bath Ankylosing Spondylitis Disease Activity Index and Health Assessment Questionnaire Disability Index score

Time Frame

Weeks 24 and 52

Title

The proportion of subjects who achieve a Disease activity score-C-reactive protein < 3.2

Time Frame

Weeks 24 and 52

Title

The proportion of subjects with active Psoriasis and Body surface area ≥ 3%

Description

Psoriasis Area and Severity Index 75, Psoriasis Area and Severity Index 90 and Psoriasis Area and Severity Index 100

Time Frame

Weeks 24 and 52

Title

The change from Baseline in the levels of "Metabolic Biomarkers"

Time Frame

at Week 24

Title

the change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)

Time Frame

at Week 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 52

Title

proportion of subjects who achieve a response based on Modified Psoriatic Arthritis Responder Criteria (PsARC)

Time Frame

at Week 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 52.

Title

change from baseline in Work Productivity and Activity Impairment Questionnaire Scores

Time Frame

at Week 12,16 24, 48 and 52

Title

change from baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)

Time Frame

at Week 8,16, 24 and 52.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Subject has provided written informed consent. Subject is ≥ 18 years of age at time of Screening. RF and anti-CCP Ab negative. Subjects must have prior exposure to anti-TNF agent(s) use for the treatment of PsO or PsA. Exclusion Criteria: Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition. Subject has an active infection or history of infections as follows: any active infection for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening, a serious infection, defined as requiring hospitalization or IV anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening, recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject. Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus. Subject had myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose. Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma. Subject has a history of malignancy within 5 years from the time of Screening EXCEPT treated and considered cured cutaneous basal or squamous cell carcinoma, in situ cervical carcinoma, OR in situ breast ductal carcinoma. Subjects with a history of alcohol or drug abuse in the previous 2 years. Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 17 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A FSH test should be performed to confirm menopause for those women with no menses for less than 1 year. Subject currently enrolled in another investigational device/procedure or drug study, or Baseline of this study is less than 30 days or 5 half-lives (whichever is longer) since ending another investigational device/procedure or drug study(s), or receiving other investigational agent(s). Subject previously has been enrolled (randomized) in this study. Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures. Donation or loss of 400 mL or more of blood within 8 weeks before dosing. Subjects who have been placed in an institution on official or judicial orders. Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Head, Clinical development

Phone

91 2266455645

Ext

5689

Clinical.Trial@sunpharma.com

Facility Information:

Facility Name

Sunpharma Site no 47

City

Anniston

State/Province

Alabama

ZIP/Postal Code

36207

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Vishala Chindalore, M.D./CCRP

Phone

256-236-0055

vchindalore@pinnacletrials.com

Facility Name

Sunpharma Site no 42

City

Dothan

State/Province

Alabama

ZIP/Postal Code

36305

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Edmond Lacour, M.D.

Phone

334-699-1632

e.laco@secclinicalresearch.com

Facility Name

Sunpharma Site no 29

City

Gilbert

State/Province

Arizona

ZIP/Postal Code

85297

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Daniel Kreutz, M.D.

Phone

480-588-6253

kreutz.research@azarthritis.com

Facility Name

Sunpharma Site no 31

City

Mesa

State/Province

Arizona

ZIP/Postal Code

85210

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Areena Swarup, M.D.

Phone

480-321-8581

swarup.research@azarthritis.com

Facility Name

Sunpharma Site no 30

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85032

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Saima Chohan, M.D.

Phone

480-626-6651

chohan.research@azarthritis.com

Facility Name

Sunpharma Site no 43

City

Scottsdale

State/Province

Arizona

ZIP/Postal Code

85258

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 35

City

Covina

State/Province

California

ZIP/Postal Code

91722

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Samy Metyas, M.D., MSc., FACR, FACP

Phone

626-869-5730

drmetyas@gmail.com

Facility Name

Sunpharma Site no 48

City

Encino

State/Province

California

ZIP/Postal Code

91436

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Joseph Raoof, M.D.

Phone

818-788-5060

joseph@drraoof.com

Facility Name

Sunpharma site no. 17

City

Fountain Valley

State/Province

California

ZIP/Postal Code

92708

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Vivian T Laquer, M.D

Phone

714-531-2966

vivian.laquer@gmail.com

Facility Name

Sunpharma site no. 15

City

Thousand Oaks

State/Province

California

ZIP/Postal Code

91320

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Navid Ezra, M.D.

Phone

805-298-7021

navid.ezra@gmail.com

Facility Name

Sunpharma Site no 40

City

Denver

State/Province

Colorado

ZIP/Postal Code

80230

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Christopher Antolini, M.D.

Phone

303-394-2828

rantolini@dacdenver.com

Facility Name

Sunpharma Site no 36

City

Fort Collins

State/Province

Colorado

ZIP/Postal Code

80528

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Michael Thakor, M.D.

Phone

970-440-2121

mthakor@tektonresearch.com

Facility Name

Sunpharma Site no 32

City

Bridgeport

State/Province

Connecticut

ZIP/Postal Code

06606

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma site no. 21

City

Clearwater

State/Province

Florida

ZIP/Postal Code

33765

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Robert Levin, M.D.

Phone

727-466-0078

Ext

225

rlevin@crwf.com

Facility Name

Sunpharma site no. 02

City

Hialeah

State/Province

Florida

ZIP/Postal Code

33016

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Carlos A Sesin, M.D.

Phone

305-456-9062

c.sesin@sweethoperesearch.com

Facility Name

Sunpharma Site no 39

City

Hollywood

State/Province

Florida

ZIP/Postal Code

33024

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 55

City

Kissimmee

State/Province

Florida

ZIP/Postal Code

34741

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Karamali Bandealy

Phone

407-750-5300

KBandealy@vidaclinicalresearch.com

Facility Name

Sunpharma Site no. 75

City

Margate

State/Province

Florida

ZIP/Postal Code

33063

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jigar Shah

Phone

954-669-1052

jshah@lifeclinicaltrials.com

Facility Name

Sunpharma site no. 19

City

Miami

State/Province

Florida

ZIP/Postal Code

33135

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Ricardo J Garcia-Alemany, M.D.

Phone

305-631-6704

rgarciamd@suncoastresearch.com

Facility Name

Sunpharma site no. 05

City

New Port Richey

State/Province

Florida

ZIP/Postal Code

34652

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Farrukh Zaidi, M.D.

Phone

727-849-4131

fzaidi@suncoastclinicalresearch.com

Facility Name

Sunpharma Site no. 76

City

Ocoee

State/Province

Florida

ZIP/Postal Code

34761

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Mariangeli Arroyo-Avila

Phone

732-800-4415

marroyo.acro@gmail.com

Facility Name

SunPharma Site no 22

City

Tamarac

State/Province

Florida

ZIP/Postal Code

33321

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Steven Kimmel, M.D.

Phone

954-545-8400

wbrakimmel@gmail.com

Facility Name

Sunpharma Site no 46

City

Gainesville

State/Province

Georgia

ZIP/Postal Code

30501

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marta T Bognar, M.D.

Phone

770-531-3711

mtb@articularishealthcare.com

Facility Name

Sunpharma Site no. 122

City

Glenview

State/Province

Illinois

ZIP/Postal Code

60201

Country

United States

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 41

City

Oak Brook

State/Province

Illinois

ZIP/Postal Code

60523

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Angela Crowley, M.D.

Phone

630-491-1900

acrowley@affinityhealthcorp.com

Facility Name

Sunpharma Site no 54

City

Orland Park

State/Province

Illinois

ZIP/Postal Code

60467

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Cory Conniff

Phone

847-599-2492

CCONNIFF@CISRESEARCH.COM

Facility Name

Sunpharma Site no 38

City

Schaumburg

State/Province

Illinois

ZIP/Postal Code

60185

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Kamran Chaudhary, M.D.

Phone

630-339-5300

kchaudhary@clsresearch.com

Facility Name

Sunpharma Site no 37

City

Skokie

State/Province

Illinois

ZIP/Postal Code

60076

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Robert Hozman, M.D., S. C

Phone

847-673-8473

rhozman@cisresearch.com

Facility Name

Sunpharma site no. 20

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67207

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Shadi H Shahouri, M.D., FACR

Phone

316-689-6683

shadi.shahouri@amrllc.com

Facility Name

Sunpharma Site no 26

City

Lake Charles

State/Province

Louisiana

ZIP/Postal Code

70605

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Enrique Mendez, M.D.

Phone

337-312-8619

emendezmd@accurateclinicalresearch.com

Facility Name

Sunpharma site no. 07

City

Worcester

State/Province

Massachusetts

ZIP/Postal Code

01605

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Charles A Birbara, M.D.

Phone

508-755-0201

cabirbara@aol.com

Facility Name

Sunpharma site no. 10

City

Lansing

State/Province

Michigan

ZIP/Postal Code

48910

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 45

City

Eagan

State/Province

Minnesota

ZIP/Postal Code

55121

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

David Ridley, M.D.

Phone

651-361-8659

dridley@sprdrem.com

Facility Name

Sunpharma site no. 14

City

Springfield

State/Province

Missouri

ZIP/Postal Code

65810

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

David G True, D.O., FACR

Phone

417-883-7889

dtrue@clinvest.com

Facility Name

Sunpharma Site no. 123

City

Webster Groves

State/Province

Missouri

ZIP/Postal Code

63119

Country

United States

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 53

City

Kalispell

State/Province

Montana

ZIP/Postal Code

59901

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Roger Diegel

Phone

406-755-1460

jwyatt@krmc.org

Facility Name

Sunpharma Site no 27

City

Lincoln

State/Province

Nebraska

ZIP/Postal Code

68516

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Melvin Churchill, M.D.

Phone

402-420-3433

Melvin.Churchill@nebraskaarthritis.com

Facility Name

Sunpharma Site no 44

City

Voorhees

State/Province

New Jersey

ZIP/Postal Code

08043

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Adrienne Hollander, M.D.

Phone

856-424-5005

drhollandertrials@arbda.com

Facility Name

Sunpharma site no. 09

City

Rochester

State/Province

New York

ZIP/Postal Code

14623

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 52

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28204

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alireza Nami

Phone

203-374-9816

anami@jmmcri.com

Facility Name

Sunpharma Site no. 73

City

Leland

State/Province

North Carolina

ZIP/Postal Code

28451

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

David Snow, M.D.

Phone

910-726-1806

dsnow@interspond.com

Facility Name

Sunpharma Site no 56

City

Wilmington

State/Province

North Carolina

ZIP/Postal Code

28401

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

George Ronald

Phone

910-815-6108

RGeorge@wilmingtonhealth.com

Facility Name

Sunpharma Site no. 119

City

Wilmington

State/Province

North Carolina

ZIP/Postal Code

28401

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Ronald George

Phone

910-815-6108

RGeorge@wilmingtonhealth.com

Facility Name

Sunpharma Site no 33

City

Minot

State/Province

North Dakota

ZIP/Postal Code

58701

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Erdal Diri, M.D.

Phone

701-857-2510

erdaldiri@yahoo.com

Facility Name

Sunpharma site no. 18

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45242

Country

United States

Individual Site Status

Suspended

Facility Name

Sunpharma site no. 11

City

Middleburg Heights

State/Province

Ohio

ZIP/Postal Code

44130

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Isam A Diab, M.D.

Phone

440-826-0742

IDIABMD@GMAIL.COM

Facility Name

Sunpharma Site no. 124

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73103

Country

United States

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma site no. 25

City

Wyomissing

State/Province

Pennsylvania

ZIP/Postal Code

19610

Country

United States

Individual Site Status

Terminated

Facility Name

Sunpharma Site no 34

City

Greenville

State/Province

South Carolina

ZIP/Postal Code

29601

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jeffrey Lawson, M.D.

Phone

864-527-2307

lawson@piedmontarthritis.com

Facility Name

Sunpharma Site no 50

City

Austin

State/Province

Texas

ZIP/Postal Code

78745

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Paul Pickrell, M.D.

Phone

512-388-5717

ppickrell@tektonresearch.com

Facility Name

Sunpharma site no. 13

City

Baytown

State/Province

Texas

ZIP/Postal Code

77521

Country

United States

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 49

City

Grapevine

State/Province

Texas

ZIP/Postal Code

76051

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Dhiman Basu, M.D./F.A.C.R

Phone

972-299-8399

dhimanbasu@pccrsolutions.com

Facility Name

Sunpharma site no. 06

City

Houston

State/Province

Texas

ZIP/Postal Code

77004

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma site no. 08

City

Houston

State/Province

Texas

ZIP/Postal Code

77084

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Amber Khan, M.D.

Phone

832-672-7973

akhanmd@accurateclinicalresearch.com

Facility Name

Sunpharma site no. 04

City

League City

State/Province

Texas

ZIP/Postal Code

77573

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Michelle Eisenberg, M.D.

Phone

210-762-6579

meisenbergmd@accurateclinicalresearch.com

Facility Name

Sunpharma Site no 28

City

Lubbock

State/Province

Texas

ZIP/Postal Code

79410

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jitendra Vasandani, M.D.

Phone

806-993-1040

jitendra.vasandani@yahoo.com

Facility Name

Sunpharma Site no. 74

City

Mesquite

State/Province

Texas

ZIP/Postal Code

75150

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Atul Singhal, M.D.

Phone

972-288-2600

asinghal@swrr.net

Facility Name

Sunpharma site no. 03

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229

Country

United States

Individual Site Status

Terminated

Facility Name

Sunpharma site no. 16

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Pendleton B Wickersham, M.D.

Phone

210-477-2626

drwickersham@cttexas.com

Facility Name

Sunpharma site no. 01

City

Tomball

State/Province

Texas

ZIP/Postal Code

77375

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Shaikh Arif Ali, M.D.

Phone

281-517-0550

drali@dmclinicalresearch.com

Facility Name

Sunpharma Site no. 121

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84132

Country

United States

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma site no. 12

City

Spokane

State/Province

Washington

ZIP/Postal Code

99204

Country

United States

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no. 81

City

Phillip

State/Province

Australian Capital Territory

ZIP/Postal Code

2606

Country

Australia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Annamma Dorai-Raj

Phone

61262828410

First Name & Middle Initial & Last Name & Degree

diana@wodedermatology.com.au

Facility Name

Sunpharma Site no. 84

City

Kogarah

State/Province

New South Wales

ZIP/Postal Code

2217

Country

Australia

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 68

City

Maroochydore

State/Province

Queensland

ZIP/Postal Code

4558

Country

Australia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Peter Nash

Phone

61754431033

drpnash@tpg.com.au

Facility Name

Sunpharma site no. 24

City

Hobart

State/Province

Tasmania

ZIP/Postal Code

7000

Country

Australia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jane Zochling, Mmed, FRACP

Phone

61-36223-8802

jzochling@southernclinicalresearch.com.au

Facility Name

Sunpharma Site no 67

City

Camberwell

State/Province

Victoria

ZIP/Postal Code

3145

Country

Australia

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no. 82

City

Fitzroy

State/Province

Victoria

ZIP/Postal Code

3065

Country

Australia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Evange Romas

Phone

03 9231 3645

fatima.sullivan@svha.org.au

Facility Name

Sunpharma Site no. 83

City

Murdoch

State/Province

Western Australia

ZIP/Postal Code

6150

Country

Australia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Helen Keen

Phone

61424180842

daniel.lightowler@uwa.edu.au

Facility Name

Sunpharma Site no. 97

City

Ontario

ZIP/Postal Code

L3P 1X2

Country

Canada

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma site 98

City

Quebec

ZIP/Postal Code

G8Z 1Y2

Country

Canada

Individual Site Status

Active, not recruiting

Facility Name

Sun pharma site 99

City

Brno

Country

Czechia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Petr Nemec

Phone

+420 545 214 556 ext:

revmatologie.nemec@seznam.cz

Facility Name

Sunpharma Site no. 100

City

Prague 2

Country

Czechia

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 101

City

Prague

ZIP/Postal Code

14000

Country

Czechia

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 96

City

Zlín

ZIP/Postal Code

760 01

Country

Czechia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Petr Vitek

Phone

61861522222

pv.medical@seznam.cz

Facility Name

Sunpharma Site no. 125

City

Sabadell

ZIP/Postal Code

8208

Country

Estonia

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 85

City

Tallinn

ZIP/Postal Code

10117

Country

Estonia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sandra Meisalu

Phone

3726109434

sandra.talli@innomedica.ee

Facility Name

Sunpharma site no. 102

City

Tallin

ZIP/Postal Code

13419

Country

Estonia

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 87

City

Tartu

ZIP/Postal Code

50106

Country

Estonia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Airi Poder

Phone

3725058949

airi.poder@std.ee

Facility Name

Sunpharma Site no. 86

City

Tartu

ZIP/Postal Code

50708

Country

Estonia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Raili Müller

Phone

3725167731

raili.myller@meditrials.ee

Facility Name

Sunpharma Site no. 89

City

Bad Doberan

ZIP/Postal Code

18209

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Gunther Neeck

Phone

+49(0)38203 -73190

gunther.neeck@biomedro.de

Facility Name

Sunpharma Site no. 91

City

Berlin

ZIP/Postal Code

12161

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jan Frederic Brandt-Juergens

Phone

4.91747E+11

info@rheumapraxis-brandt-juergens.de

Facility Name

Sunpharma Site no. 90

City

Berlin

ZIP/Postal Code

13125

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Andreas Krause

Phone

+49 30 94792300

andreas.krause@immanuelalbertinen.de

Facility Name

Sunpharma Site no. 103

City

Herne

ZIP/Postal Code

44649

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Xenofon Baraliakos

Phone

+49 2325 592 ext: 131

Xenofon.Baraliakos@elisabethgruppe.de

Facility Name

Sunpharma Site no. 120

City

Brescia

ZIP/Postal Code

25123

Country

Italy

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 104

City

Milan

ZIP/Postal Code

20089

Country

Italy

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 126

City

Daejeon

ZIP/Postal Code

35015

Country

Korea, Republic of

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 69

City

Incheon

ZIP/Postal Code

22332

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Won Park

Phone

82328903483

parkwon@inha.ac.kr

Facility Name

Sunpharma Site no 72

City

Seoul

ZIP/Postal Code

16499

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Chang-Hee Suh

Phone

82-31-219-5118

hopeajou@aumc.ac.kr

Facility Name

Sunpharma Site no 71

City

Seoul

ZIP/Postal Code

3080

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

EunBong Lee

Facility Name

Sunpharma Site no 70

City

Seoul

ZIP/Postal Code

4763

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Chan-Bum Choi

Phone

82-2-2290-9208

angeloeye@naver.com

Facility Name

Sunpharma Site no. 95

City

Warsaw

State/Province

Mazowiecki

ZIP/Postal Code

05-830

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marek Krogulec

Phone

48227298856

marekkrogulec@wp.pl

Facility Name

Sunpharma Site no. 93

City

Bialystok

ZIP/Postal Code

15-879

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Anna N. Nowak

Phone

48669142505

nowak@clinicmed.pl

Facility Name

Sunpharma Site no. 110

City

Białystok

ZIP/Postal Code

15-351

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Arthur Racewicz

Facility Name

Sunpharma Site no. 94

City

Krakow

ZIP/Postal Code

30-033

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Grazyna Pulka

Phone

48124223271

allmedpl@gmail.com

Facility Name

Sunpharma Site no. 109

City

Krakow

ZIP/Postal Code

30-510

Country

Poland

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 107

City

Lublin

ZIP/Postal Code

20-607

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Dariusz Chudzik

Phone

48517226631

dariuszbchudzik@wp.pl

Facility Name

Sunpharma Site no. 106

City

Ponzan

ZIP/Postal Code

60-529

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zygmunt Adamski

Phone

+48 61 841 17 24 ext:

prof.adamski@gmail.com

Facility Name

Sunpharma Site no. 92

City

Poznan

ZIP/Postal Code

61-113

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Anna Rychlewska-Hanczewska

Phone

48603309321

a.hanczewska@wp.pl

Facility Name

Sunpharma Site no. 108

City

Torun

ZIP/Postal Code

87-100

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Slawomir Jeka

Phone

+48 523 655 520 ext:

s.jeka@wp.pl

Facility Name

Sunpharma Site no. 111

City

Warszawa

ZIP/Postal Code

02-118

Country

Poland

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Maria Rell-Bakalarska

Phone

+48 501 792 039 ext:

rell-bakalarska@wp.pl

Facility Name

Sunpharma Site no. 88

City

Martin

ZIP/Postal Code

3601

Country

Slovakia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Viliam Manka

Phone

421 902283047

vilcoo@gmail.com

Facility Name

Sunpharma Site no. 113

City

Rimavska Sobota

ZIP/Postal Code

97901

Country

Slovakia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Viola Husarova

Phone

421908920669

husarov001@gmail.com

Facility Name

Sunpharma Site no. 114

City

Svidnik

ZIP/Postal Code

8901

Country

Slovakia

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no. 112

City

Vahom

ZIP/Postal Code

91501

Country

Slovakia

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marianna Hauptvoglova

Phone

+421911406561 ext:

hauptvoglova2@centrum.cz

Facility Name

Sunpharma Site no. 115

City

A Coruña

ZIP/Postal Code

15706

Country

Spain

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 57

City

Cordoba

ZIP/Postal Code

14004

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alejandro Escudero Contreras

alejandro.escudero.sspa@juntadeandalucia.es

Facility Name

SunPharma Site No 23

City

Córdoba

ZIP/Postal Code

14004

Country

Spain

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alejandro Escudero Contreras, Degree in Med.

Phone

34957010429

alejandro.escudero.sspa@juntadeandalucia.es

Facility Name

Sunpharma Site no. 118

City

Gran Canaria

ZIP/Postal Code

35010

Country

Spain

Individual Site Status

Active, not recruiting

Facility Name

Sunpharma Site no 58

City

La Coruña

ZIP/Postal Code

15006

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Francisco Javier Blanco Garcia

Phone

981176398

fblagar@sergas.es

Facility Name

Sunpharma Site no. 78

City

Madrid

ZIP/Postal Code

28046

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Alejandro Balsa

Phone

34917277193

alejandro.balsa@salud.madrid.org

Facility Name

Sunpharma Site no. 116

City

Malaga

ZIP/Postal Code

29009

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Antonio Fernandez Nebro

Phone

34951029000

afnebro@gmail.com

Facility Name

Sunpharma Site no. 77

City

Sevilla

ZIP/Postal Code

41013

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Paula Cejas

Phone

34664472474

pcejashil@gmail.com

Facility Name

Sunpharma Site no. 117

City

Sevilla

ZIP/Postal Code

41014

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Raquel Hernandez Sanchez

Facility Name

Sunpharma Site no 59

City

Valencia

ZIP/Postal Code

46010

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Pilar Trenor Larraz

Phone

34961973787

reumaensayosclinico@gmail.com

Facility Name

Sunpharma Site no 51

City

Valencia

ZIP/Postal Code

46026

Country

Spain

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 65

City

Taipei

State/Province

Pai-Tou

ZIP/Postal Code

112

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hsiao-Yi Lin

Phone

886-933-7-399

doc1116d@gmail.com

Facility Name

Sunpharma Site no 63

City

Jianguo

State/Province

Taichung

ZIP/Postal Code

402

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

James Cheng-Chung Wei

Phone

886 4-2473 9595

wei3228@gmail.com

Facility Name

Sunpharma Site no. 79

City

Hsinchu

ZIP/Postal Code

300

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hsien-Yi Chiu

Phone

886-928-186-936

extra.owl0430@yahoo.com.tw

Facility Name

Sunpharma Site no. 80

City

Kaohsiung

ZIP/Postal Code

80756

Country

Taiwan

Individual Site Status

Withdrawn

Facility Name

Sunpharma Site no 62

City

Kaohsiung

ZIP/Postal Code

833

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Ji-Chen Ho

Phone

8.86976E+11

jichenho@cgmh.org.tw

Facility Name

Sunpharma Site no 61

City

Taichung

ZIP/Postal Code

704

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Joung-Liang Lan

Phone

886 937759007

jll.trial@gmail.com

Facility Name

Sunpharma Site no 60

City

Tainan

ZIP/Postal Code

710

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hung-An Chen

Phone

88662812811

hachen801039@yahoo.com.tw

Facility Name

Sunpharma Site no 64

City

Taipei

ZIP/Postal Code

112

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yun-Ting Chang

Phone

+886 4-24739595

qwer741214@yahoo.com.tw

Facility Name

Sunpharma Site no 66

City

Taipei

ZIP/Postal Code

114

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hsiang-Cheng Chen

Phone

886287923311

hccheng@mail.ndmctsgh.edu.tw

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

We'll reach out to this number within 24 hrs

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active Psoriatic Arthritis

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial